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Decision analysis, an analytic approach to making decisions 
when uncertainty is present, has its foundation in proba- 
bility and utility theory. It provides insights into the 
trade-offs that are involved when a selection must be made 
among patient management strategies. In general, several 
broad steps are involved. The process begins by formulat- 
ing the clinical problem as a well focused choice among a 
limited set of clinical etiologies. These strategies are then 
structured explicitly in a model that depicts the clinical 
events that may ensue from each option. By assigning 
Decision-Making Strategies for 
Individual Patients 
Clinical decision analysis (l-3), an analytic approach to 
making decisions when uncertainty is present, has its foun- 
dations in probability theory and utility theory; it has been 
applied to medical problems for the last I5 years. Such 
analyses afford the decision maker insights into the trade- 
offs that must be made when selecting among management 
strategies, either implicitly or explicitly. Although these 
techniques are most commonly applied to large groups of 
patients, they can also be applied to individual patients. 
What sets patient analyses apart from generic clinical deci- 
sion models are the accommodations they contain for the 
unique characteristics of the individual. Such analyses con- 
sider the constellations of co-morbid conditions that charac- 
terize the individual and limit the benefits he or she may 
derive from diagnostic and therapeutic interventions. Such 
analyses can also reflect personal preferences of the individ- 
ual, obtained during patient interview, by using utility as- 
sessment techniques. Typically, such analyses take the 
perspective of the patient rather than society, the hospital or 
the reimbursement agency. 
From the Division of Clinical Decision Making, Department of Medicine. 
New England Medical Center. Boston. Massachusetts. This study was 
supported in part by Research Grant 4493 from the National Library of 
Medicine. Bethesda. Maryland. 
Address for renrints: Stephen G. Pauker. MD, New England Medical 
Center. 750 Washington Street. Boston. Massachusetts 0211 I. 
probability values to each outcome, the weighted average 
outcome or expected utility can be calculated for each 
alternative strategy. The strategy with the highest expected 
utility is the optimal one. 
The methods of decision analysis offer a number of 
distinct advantages. These include: 1) providing a structure 
with which to simplify and focus clinical dilemmas; 2) 
providing a forum for discussing clinical reasoning; and 3) 
developing a consensus among groups of decision makers. 
(J Am CON Cardiol1989;14:29A-37A) 
As practitioners of clinical decisron analysis, we com- 
monly offer consultations to colleagues faced with perplexing 
clinical management problems. Although each patient we 
consider is unique, for clinical circumstances that we see 
repeatedly we develop template decision models. One com- 
monly encountered cardiologic problem is the determination 
of the optimal time for semielective surgery in patients with 
serendipitously discovered evidence of an interval myo- 
cardial infarction, e.g., new Q waves on the preoperative 
electrocardiogram (ECG). A dilemma arises because operat- 
ing immediately exposes the patient to the high operative 
mortality rates experienced by patients with recently in- 
farcted myocardium, whereas delaying surgery exposes the 
patient to the potential complications of underlying surgical 
problems. 
Illustrative cases. Clearly, this preoperative predicament 
can have many different presentations. For example, we 
recently encountered a 73 year old man with a history of 
prostatic hypertrophy and excised colonic carcinoma 
(Duke’s A) who was admitted to the hospital with bladder 
outlet obstruction. Because a Foley catheter could not be 
inserted, a suprapubic catheter was placed and the patient 
was scheduled for a transurethral prostatectomy. An ECG 
obtained as part of his preoperative evaluation revealed Q 
waves in the inferior leads that were distinctly broader than 
those on his last ECG obtained 6 months earlier. The patient 
had had no chest pain or other symptoms to suggest myo- 
cardial infarction. A radionuclide ventriculogram revealed a 
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Figure 1. Probability of perioperative myocardial infarction (MI) up 
to 6 months after myocardial infarction. 
normal left ventricular ejection fraction (60%) and no seg- 
mental wall motion abnormalities. At this juncture, the 
urologist caring for the patient asked two questions: I) did 
the patient have a myocardial infarction; and 2) if so, 
how long should surgery be delayed? From a cardiologic 
perspective alone, waiting 6 months would be prudent 
because the risk of a perioperative infarction declines 
with time (4,5) (Fig. 1): reaching a relatively stable base 
level at approximately 6 months after infarction. Thus, a 
delay of 6 months should be adequate even after an 
acute myocardial infarction. However, a 6 month delay 
with a suprapubic catheter would disrupt the patient’s life, 
be uncomfortable, engender frequent evaluation by a 
urologist and expose the patient to the risks of life- 
threatening sepsis. 
We were faced with a similar predicament when an 81 
year old woman with diabetes mellitus slipped in the shower 
and fractured her right hip. Preoperative evaluation dis- 
closed new lateral wall Q waves not present on the ECG 
obtained 6 months earlier. She gave no history of chest pain 
and the echocardiogram revealed a left ventricular ejection 
fraction of 55% and no segmental wall motion abnormalities. 
Once again, the surgeon needed to know whether the patient 
sustained a new myocardial infarction and how long surgery 
should be delayed. 
Determining the optimal time for surgery with decision 
analysis. Although neither patient had a history of chest pain 
that correlated with the ECG findings, silent myocardial 
infarctions do occur. A transmural myocardial infarction 
might be expected to provide some segmental wall motion 
abnormality or a reduced left ventricular ejection fraction, at 
least transiently. To determine the likelihood that each 
patient sustained an infarction, we must consider both the 
“positive” ECG and the “negative” radionuclide ventricu- 
logram or echocardiogram. 
Even if we knew with certainty that each patient sus- 
tained a myocardial infarction, we still would not know 
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Figure 2. Probability of myocardial infarction (MI) at 0 to 6 months 
before evaluation. 
precisely when in the last 6 months it took place (Fig. 2). 
This makes it more difficult to determine the optimal time for 
surgery. The optimum occurs when the decreasing risk and 
consequences of a perioperative infarction and the increas- 
ing risk from complications of the underlying surgical dis- 
ease are at a combined minimum. 
In this report we discuss some of the techniques used in 
performing a clinical decision analysis for the individual 
patient in the context of this common preoperative predica- 
ment. The decision model that we developed is adaptable to 
many patients with nonprogressive illnesses who are in need 
of surgery and who are found to have evidence of a myocar- 
dial infarction of indeterminate age. We illustrate this model 
in the context of the first patient described, the 73 year old 
man with bladder outlet obstruction. 
Methods 
In general, decision analysis methods involve several 
broad steps. The process begins by formulating the clinical 
problem as a well focused choice among a limited set of 
clinical strategies. These strategies are then structured ex- 
plicitly in a model such as a decision tree, which depicts the 
clinical events that may ensue from each option. By assign- 
ing probability values to each chance event and utility values 
(measures of relative worth) to each outcome, the weighted 
average outcome or expected utility can be calculated for 
each alternative strategy. The strategy with the highest 
expected utility is the optimal one. The analysis can then be 
repeated, substituting reasonable ranges of values for each 
probability and utility value in the decision tree to determine 
if and when the optimal strategy changes. This latter process 
is called sensitivity analysis. 
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Table 1. Effect of Electrocardiographic Q Waves and a Negative Radionuclide Ventriculogram on 
the Likelihood of Myocardial Infarction 
A: B: 
Initial Relative 
Likelihood Likelihood C: 
Possible of Each Widened Q Product 
Causes Cause Wave5 (A x B) 
--_-_ _I_ ----~ _. _- 
Effect of Q Waves on the Likelihood of MI 
D: 
Revised 
Likelihood of 
Each Use 
(C/I) 
- 
Recent MI 0.0018 0.75 0.0014 0.583 
No recent Ml 0.9982 0.0010 0.001 0.417 
Z = 0.0024 
Effect of Negative Radionuclide Ventriculogram on the Likelihood of MI 
~_.. _ . -- 
Relative 
Likelihood 
of Negative 
Ventriculogram 
Recent MI 0.583 0.20 0.1 I7 0.228 
No recent Ml 0.417 0.95 0.396 0.772 
-- 
2: = 0.513 
MI = myocardial infarction 
Bayes’ Rule 
Reconciling conflicting evidence on the likelihood of myo- 
cardial infarction. Our first task in analyzing the predica- 
ment of the 73 year old man is to reconcile the conflicting 
pieces of evidence (inferior Q waves and a normal radionu- 
elide ventriculogram) about the presence or absence of a 
myocardial infarction. Interpreting the results of these tests 
probabilistically, we can combine these predictions into a 
single likelihood that the patient sustained an infarction. 
Unfortunately, physicians frequently make errors when in- 
tuitively combining probabilities. Bayes’ rule (6) offers an 
explicit method for combining prior beliefs (e.g., the likeli- 
hood that the patient had an infarction) with our conditional 
beliefs that a specific test result occurs in patients with that 
diagnosis (e.g., normal radionuclide ventriculogram in pa- 
tients with a recent infarction). 
Probability 
(Diagnosis 1 Finding) = 
Probability (Diagnosis AND Finding) 
Probability (Finding) 
Expressed here in equation form, Bayes’ rule states that 
given a finding, the probability of a particular diagnosis 
(ProbabilitylDiagnosis ( Finding]) is equal to the joint pro- 
bability of the diagnosis and the finding (Probability[Diag- 
nosis AND Finding]) divided by the probability of the 
finding (Probability[Finding]). The probability of the find- 
ing, the denominator, is actually the sum of the joint prob- 
abilities of the finding and each possible diagnosis in the 
differential. 
The tabular approach to applying Bayes’ rule (Table 1). 
Despite the compactness of this formula, its direct use is by 
no means foolproof. A number of creative methods have 
been devised by applying Bayes’ rule; we shall demonstrate 
the tabular approach (7), which we believe to be the most 
straightforward of the lot. Table 1 shows two applications of 
Bayes’ rule, the first to incorporate the ECG findings and the 
second to incorporate the radionuclide ventriculographic 
findings. 
The electrocardiographicfindings. We start by listing the 
possible diagnoses for the patient in the first column and then 
our prior belief in the likelihood that the patient has each; 
i.e., we assign a probability to our belief about the presence 
of each diagnosis before obtaining the test result. In this 
example we are only interested in diagnosing myocardial 
infarction and can, therefore, lump the rest of the diagnostic 
possibilities into the “no recent myocardial infarction” 
category. Before obtaining the ECG, we had no reason to 
believe that this patient had any greater likelihood of having 
sustained a subclinical infarction than had any other osten- 
sibly healthy man his age. We estimated this probability to 
be 0.18% (0.0018). We based this estimate on data from the 
Framingham study, which revealed that the 6 month proba- 
bility of 73 year old men developing an infarction is roughly 
0.7 percent (0.0071) (8) and the overall likelihood that the 
infarction would be silent is 25% (0.25) (9,lO). Our estimate 
is the product of these two probabilities. The prior probabil- 
ity of “no recent myocardial infarction” is, therefore, 0.9982 
(99.82%). 
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Figure 3. Seven branches of the square decision node correspond- 
ing to the seven available strategic options. MI = myocardial 
infarction. 
We then listed the probability of finding Q waves with 
each of the diagnoses listed. Nontransmural myocardial 
infarctions constitute roughly 25% (11) of all myocardial 
infarctions. Thus, we would expect to find Q waves in about 
75% of all myocardial infarctions. We estimated that inferior 
Q waves would be present in 0.1% (0.001) of all of the other 
diagnoses (designated “no recent myocardial infarction”) 
related to rightward shifting of the vertical axis of the heart 
from other causes such as underlying pulmonary disease. 
We then calculated the revised probability of infarction by 
multiplying the prior probability of each diagnosis by the 
conditional probability of finding Q waves with each. The 
results are entered in column C. Each product in column C 
reflects the relative frequency of that diagnosis producing Q 
waves in a cohort of patients exactly like ours. To normalize 
the frequencies in column C, we divide each individual entry 
by the column sum. These values are entered into column D 
and represent the revised or posterior likelihood that the 
patient had either diagnosis. After consideration of the ECG 
finding, the patient had a 58.3% (0.583) probability of having 
had a transmural myocardial infarction. 
The radionuclide jindings. The second application of 
Bayes’ rule proceeds in exactly the same manner. The prior 
probabilities we use here are the revised probabilities based 
on the ECG findings, i.e., the likelihood just before obtaining 
the radionuclide ventriculogram. We estimated that a nor- 
mal radionuclide ventriculogram can be found in 20% of 
patients with recent myocardial infarction and in 95% of 
healthy 73 year old men with no recent infarction. After 
taking the negative radionuclide ventriculogram into con- 
sideration, the probability that this patient sustained an 
infarction is 22.8% (0.228), calculated in column D. We can 
now use this revised probability to determine the optimal 
time for surgery. 
Structuring the Problem 
Determining the optimal time for surgery. The objective 
of this next phase of the analysis is to determine the optimal 
time for prostatectomy given a 23% chance of a myocardial 
infarction occurring some time in the last 6 months. To make 
our task more tractable, we confined our evaluation to seven 
strategic options: operate now, wait 1 month, wait 2 months, 
up to waiting 6 months, corresponding to seven branches of 
the square decision node at the left margin of Figure 3. Each 
of the seven branches of this decision node attaches to the 
circular chance node occurring after the bracket. This 
chance node encodes our knowledge about when and if a 
myocardial il tarction took place. The Q waves may repre- 
sent an acute myocardial infarction (top branch of chance 
node), a myocardial infarction that occurred 1 to 6 months 
ago (middle six branches of chance node) or no infarction at 
all (bottom branch of chance node). The likelihood that each 
of these chance events represents this patient’s true state of 
health is not equivalent. Without either some evidence of 
abnormality on the ventriculogram or repolarization changes 
on the ECG, the infarction is more likely to be old than fresh 
(Fig. 2). The probabilities used for each of these chance 
events and all other parameters used in the model are listed 
in Table 2. 
Preoperative risks. Each of these eight branches leads to 
a subtree that models events that may occur preoperatively. 
The patient may sustain a complication of the surgical 
condition for which treatment is being delayed (in this case, 
sepsis). He may die of such a complication. He may also 
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Table 2. Probabilities of Variables Used to Determine Optimal 
Time for Surgery ----.__ - _.-- --_ _...- 
Variable Name Value 
-____. .___ ---- 
Monthly rate of developing sepsis with indwelling 0.012* 
catheter 
Sepsis mortality rate 0.01” 
Prior probability of Ml 0.228* 
Age of MI at tmte of preoperative evaluation $ 
Incidence of Ml at age 73 0.007 l/half year”’ 
Probdbilrty MI would be silent “,75’h”” _ 
Probability Ml would be transmural 0.75”” 
Probability of finding Q waves with “no recent Ml” O.OOl* 
Probability of normal ventriculogram after Ml 0.20* 
Probability of normal ventriculogram with “no 0.95* 
recent MI” 
Probability of perioperative MI 4 
Probability of reinfarction in first 6 months dfter Ml o.u75* 
Mortality of MI 0.40* 
Base monthly mortality rate: 73 year old men UUO83’” 
Excess monthly mortality rate: treated Duke’s A colon 0.0008’” 
cancer 
Excess monthly niortahty rate: coronary artery dtsedse OUU6” 
~____ _~ _-- .- _ --_- 
*Subjective estimate of domain expert: tsee Bayes’ rule section of text for 
details of calculation: $see Figure 2: Bsee Figure I. 
have a myocardial infarction, which may be fatal, while 
waiting for surgery. He may also die from other causes. 
Although these three independent events could occur in 
any order, the likelihood of each is reasonably low, so 
there is little loss of generality in the decision tree shown 
in Figure 3, which assumes that a patient who dies of 
sepsis would not have had a nonfatal infarction before such 
a death. In fact, our calculations allow for the possibility of 
more than one event. The probability of all three of these 
events depends on the length of time that surgery is delayed. 
Obviously, the risk of a preoperative infarction also depends 
on whether a recent infarction has occurred and, if so, when 
it occurred. Each of the fatal outcomes in this section of the 
model is associated with a rather abbreviated quality- 
adjusted life expectancy, the calculation of which we discuss 
herein. 
Perioperative risks. Patients who come to surgery are at 
risk for perioperative events that are modeled by the next 
section of the tree. These patients may have a perioperative 
myocardial infarction, which may be fatal or nonfatal. The 
likelihood of such events declines with increasing delay after 
an infarction-either one that had already occurred or the 
one that occurs while the patient is waiting for surgery. 
Patients who do not sustain a perioperative cardiovascular 
event are at risk for other fatal and nonfatal perioperative 
complications. 
Postoperative risks. Patients who survive the periopera- 
tive period are still at risk for the postoperative myocardial 
infarction (which could be fatal) and for death from other 
causes. We model such late events to avoid bias in the 
analysis: without this last subtree, patients who come to 
surgery early will have a shorter window of exposure to 
death from other causes and from myocardial infarction. 
The time horizon for the explicit events in this decision 
tree is 6 months. Events occurring beyond that horizon are 
accounted for in the utility values associated with each 
terminal or outcome branch. In the present case, the utility 
metric is quality-adjusted life expectancy. Depending on 
when the surgery is performed, the preoperative period can 
be up to 6 months long and the postoperative period can be 
up to 5 months long. The perioperative period is defined as 1 
month long. 
Assigning the Utilities 
Declining exponential approximation of life expectancy. 
This method (the DEALE [ 14,151) is used to estimate the life 
expectancy of the individual patient. The method is based on 
a simple declining exponential curve of the form e-@. Life 
expectancy, which is the area under this smooth curve, is 
calculated by the reciprocal of the mortality rate (l/p) and 
has been shown empirically to be a close approximation of 
the area beneath actual plotted survival curves of cohorts of 
similar patients if the Al. used is an appropriate “effective 
average mortality rate.” Although actual yearly mortality 
rates increase exponentially with age, the “DEALE” 
uses an average yearly mortality rate to calculate survival. 
This average rate is composed of several parts: the base 
average mortality rate, which is determined by the demo- 
graphics of age, gender and race and is calculated as the 
reciprocal of the normal life expectancy (found in standard 
tables of vital statistics of presumably healthy persons); 
and the excess mortality rates imposed by each of the 
disease processes from which the patient suffers (obtained 
from various sources in medical publications and expert 
clinical opinion). 
The life expectancy of a person who has several diseases 
is found by adding the base mortality rate (pLbase) to the 
excess mortality rates of each disease and taking the recip- 
rocal of that sum: 
Life expectancy z 
hsw f bkiiwasrl t hhrea\eZ t t PdirrareN 
For the example patient who is 73 years old and has 
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coronary artery disease and colon cancer, the calculation 
proceeded as follows: 
I I I 
Phase = c-z 
Normal life expectancy IO years 120 months 
= 0.0083. 
Life expectancy = 
I 
pbabe f /-&easel t /-kolonCA 
I 
= 
0.0083 t 0.006 t 0.0008 
= 66.23 months = 5.52 years. 
Not considering this patient’s immediate medical problems, 
bladder outlet obstruction in need of surgical repair, the 
patient’s life expectancy is about 5.5 years. The technique 
results in reasonable approximations of life expectancy even 
when diverse sets of excess mortality rates are combined. 
The method is easy to use because independent mortality 
rates can be combined by simple addition. The only other 
means for deriving life expectancy for an individual patient 
with a constellation of disease processes would be by 
performing a lengthy simulation or by finding a survival 
study of a cohort of patients identical to the one under 
consideration. 
Quality-adjusted life expectancy. This is used for the 
decision model described here: life expectancy, as just 
calculated, is adjusted for the short-term loss of quality of 
life imposed by the suprapubic catheter and by hospitaliza- 
tion for myocardial infarction, surgery and sepsis. The 
quality adjustments can reflect the patient’s assessment of 
quality of life under various conditions. Time spent in the 
hospital was believed to be worth half that spent out of the 
hospital. If the hospitalization period for nonfatal myocardial 
infarctions was 10 days, we subtracted 5 days (10 days at half 
quality) from the patient’s total life expectancy to adjust for 
that undesirable experience. If the patient had two myocar- 
dial infarctions, we subtracted 10 days, and so forth. Quality 
adjustments for sepsis followed precisely the same logic. 
Days in which the patient had an indwelling suprapubic 
catheter were assessed to be worth 90% of full quality; we 
therefore subtracted 10% of the days spent with the catheter 
to adjust for the lost quality of life from that undesirable 
experience. 
Results 
Applying the decision model to the individual patient (Fig. 
4). Applying this decision model to our patient we obtained 
the results displayed in Figure 4. The number of months that 
surgery was delayed is on the horizontal axis and expected 
utility, measured in quality-adjusted life-months, is on the 
vertical axis. The longer we wait, the greater the patient’s 
survival, which actually peaks at 5 months, although the 
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Figure 4. Quality-adjusted life-months versus number of months of 
delay before operating. 
curve is rather flat after 4 months. The differences between 
the strategies are extremely small, only 0.62 quality-adjusted 
months between operating now and waiting 5 months, a 
difference constituting 1% of the patient’s life expectancy. 
Asking “what if” questions (Fig. 5). As we mentioned 
earlier, performing a decision analysis for the individual 
patient offers more than just an answer-it offers decision 
makers the unique opportunity to gain insight into the 
implicit trade-offs of the decision by allowing them to ask the 
question “what if.” What if the patient’s initial probability of 
myocardial infarction was higher or what if the patient’s 
potential for surviving sepsis was lower? Figure 5, a one-way 
sensitivity analysis, addresses the first question. On the 
horizontal axis is the number of months delayed before 
performing surgery and on the vertical axis expected utility, 
measured in quality-adjusted life-months. Each of the curves 
represents a different initial probability of myocardial infarc- 
tion. If we were certain that the patient had a myocardial 
Figure 5. Quality-adjusted life-months versus number of months of 
delay before surgery at various prior probabilities of myocardial 
infarction (MI). 
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Figure 6. Quality-adjusted life-months versus months of delay be- 
fore operating at various mortality rates of sepsis. 
infarction (probability of myocardial infarction equal to 1, 
bottom curve), the least desirable time for surgery is now; 
the longer we delay surgery the greater the expected benefit 
of the procedure. As the initial probability of myocardial 
infarction declines (moving from the curve on the bottom 
toward the curve on top), the benefit of waiting declines. 
When the initial probability of infarction is as low as 0.2, the 
curve is so flat that there is essentially nothing to gain by 
delaying surgery beyond 1 month. When the initial probabil- 
ity of myocardial infarction approaches zero, any delay in 
surgery reduces the patient’s life expectancy; without the 
benefit of reducing the perioperative mortality rate, waiting 
serves only to expose the patient to the risk of sepsis and the 
discomfort from an indwelling catheter. 
Complications of underlying surgical disease (Fig. 6 and 7). 
Figure 6 demonstrates how complications of the underlying 
surgical disease (in this case sepsis) affect the selection of the 
optimal strategy. Again, the horizontal axis is the number of 
Figure 7. Quality-adjusted life-months versus months of delay be- 
fore operating with a 10 factor increase in the underlying sepsis rate. 
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Table 3. Dollar Cost for Hospitalized Care* 
Condition cost 6) 
Myocardial infarction 7,185 
Sepsis 15,000 
Prostatectomy 6,357 
Monthly cost for suprapubic catheter 125t 
*I987 data from urban teaching hospital; tsubjective estimate. 
months of delay before surgery and the vertical axis is 
expected utility, measured in quality-adjusted life-months. 
Each curve is at a different mortality rate for sepsis. As the 
mortality of sepsis increases, i.e., as we move from the 
upper curve to lower curves, the optimal delay for surgery 
decreases. When the mortality rate of sepsis is zero, the 
longer we wait the higher the yield. However, when the 
mortality rate of sepsis is ~0.2, the curves reach a peak; 
waiting longer or shorter than the peak delay time results in 
a less than optimal expected utility. The optimal surgical 
delay when the mortality rate of sepsis is 5% (0.05) is 4 
months, and when the mortality rate is 25% (0.25) it is I 
month. As would be expected, the optimal delay for surgery 
decreases as the mortality from complications of the under- 
lying surgical illness increases. In fact, when the rate of 
sepsis is higher, this effect is even more marked. Figure 7 
provides essentially the same sensitivity analysis as Figure 
6, but we have increased the underlying sepsis rate by a 
factor of 10, from 1.2% (0.012) to 12% (0.12). Increasing the 
rate at which sepsis develops causes the quality-adjusted 
survival to decline for all mortality rates of sepsis above 
zero. At zero, the curve actually peaks at 4 months because 
of the morbidity associated with a catheter; waiting for a 
longer or shorter time than 4 months would be suboptimal, 
although the absolute difference in quality-adjusted life ex- 
pectancy is quite small. 
Cost-effectiveness analysis (Tables 3 and 4, Fig. 8). Al- 
though these results take into consideration pain and suf- 
fering, they do not reflect the monetary expenses involved 
with each option. To choose among these closely valued 
alternatives, we now consider the relative cost and effective- 
ness of each. Cost-effectiveness analysis (16) follows the 
same analytic steps that we outlined earlier, with the excep- 
tion that we must carry through the analysis with two utility 
metrics, cost and quality-adjusted life expectancy. The costs 
for hospitalized care for myocardial infarction, transurethral 
prostatectomy and sepsis are listed in Table 3. These total 
costs were derived from an urban teaching hospital data base 
in 1987. In addition to hospital care, there is a monthly cost 
for outpatient maintenance for the suprapubic catheter. 
Table 4 lists the effectiveness, total cost, marginal cost, 
marginal effectiveness and marginal cost-effectiveness ratio 
for each of the seven strategies. The table entries are ordered 
by total cost. The marginal or incremental gains and losses 
reflect comparisons of consecutive strategies. The marginal 
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Table 4. Analysis of Cost-Effectiveness of Seven Treatment Strategies 
Strategy 
Cost 
($) 
Quality- 
Adjusted 
Survival 
(months) 
Marginal 
cost* ($1 
Marginal 
Quality- 
Adjusted 
Survival* 
(months) 
Marginal Cost- 
Effectiveness*tB 
($/year) 
Operate now 6.437 66.35 - - - 
Wait I month 6,674 66.63 237 0.28 10.000 
Wait 2 months 6.926 66.80 252 0.18 17,000 
Wait 3 months 7.188 66.91 262 0.10 31.000 
Wait 4 months 7,458 66.96 269 0.05 66,000 
Wait 5 months 7,732 66.97 274 0.01 237,000 
Wait 6 months 8.010 66.96 277 -0.01 f 
*Compared with the prior strategy: tcost per quality-adjusted life-year gained is calculated by dividing column 
four by column five and multiplying by 12: #dominated by preceding strategy (both costs more and offers less efficacy 
than preceding strategy); grounded to two places. 
cost-effectiveness ratio describes how much additional sur- 
vival is obtained with each additional dollar spent: i.e., it is 
the rate paid for each additional bit of survival gained. 
The analysis revealed that operating now would cost 
$6,437 and that operating in 5 months, which is the most 
effective strategy, would cost $7,732. Note that waiting 6 
months is both more costly and less effective than waiting 5 
months and is, therefore, dominated, allowing us to elimi- 
nate it from consideration. Although the total cost difference 
for the range of strategies being considered is only $1,259, 
the incremental rate that we pay for each strategy differs 
considerably. The added survival gained by waiting 1 month 
rather than operating now would cost $10,000 per year of life 
gained, whereas waiting 5 months to operate instead of 4 
would cost $237,000 per year of life gained. Thus, the rate we 
pay for each additional bit of life gained by delaying surgery 
increases dramatically after the first few months. 
Although there are no established guidelines for deter- 
mining how much one should be willing to pay for the 
increased survival, it is helpful to compare our results with 
Figure 8. Effect of prior probability of myocardial infarction on the 
cost of quality-adjusted life-years gained. 
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the cost-effectiveness of other accepted and commonly 
employed procedures. For example, antihypertensive ther- 
apy is reported (17) to cost about $15,000 per year of life 
gained for moderately severe hypertension. Coronary by- 
pass graft surgery is reported (18) to cost about $20,000 per 
year of life gained for patients with moderate to severe 
angina pectoris. Renal dialysis is estimated to cost in excess 
of $50,000 per year of life gained and bone marrow trans- 
plantation is estimated to cost over $100,000 per year of life 
gained. 
Figure 8 illustrates the effect of prior probability of 
infarction on the marginal cost-effectiveness of the most 
eflective strategy, waiting 5 months over that of waiting 4 
months. The vertical axis is the marginal cost-effectiveness 
ratio, measured in dollars per year of quality-adjusted life 
expectancy gained and the horizontal axis is the prior 
probability of myocardial infarction. Our base case prior 
probability of myocardial infarction estimate is 23%. The 
absence of points on the curve below 20% (0.2) means that 
waiting 5 months is dominated by waiting 4 months when the 
prior probability is below that value; as we approach that 
value, the marginal price of life gained increases sharply. 
Delaying surgery that extra month, when the probability of 
myocardial infarction is 20%, costs roughly $1 million per 
year of quality-adjusted life gained-roughly 10 times the 
rate paid for bone marrow transplantation. 
Discussion 
The decision of when to perform transurethral prostatec- 
tomy in this patient is, indeed, a close call. The expected 
benefit of delaying surgery steadily increased over the first 5 
months; however, >90% of the potential benefit achieved by 
delaying surgery was achieved within the first 3 months of 
delay; therefore, 3 months should be the minimal time that 
we delay surgery. 
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Limitations of the model. Although this analysis is tai- 
lored to one specific patient, the basic model itself is 
adaptable to a wider group of patients and other settings. It 
is important to realize, however, that decision models are 
merely approximations to clinical reality and are designed to 
answer a few focused questions. Thus, considerable discre- 
tion is required in adapting them to different patients and 
clinical circumstances. For example, the model that we 
constructed here does not make provision for progression of 
the underlying surgical disease; therefore, when the under- 
lying surgical disease is cancer, it would not model the 
possibility that a delay in surgery might preclude a surgical 
cure. Such problems are, in fact, approachable by decision 
analysis techniques and have been addressed elsewhere (19). 
Advantages of decision analysis for clinical problem solv- 
ing. The explicit and normative methods of decision analy- 
sis offer a number of distinct advantages for clinical problem 
solving: 1) they provide the structure to simplify and focus 
clinical dilemmas; 2) they offer simple algorithms for dealing 
with probabilities; 3) they allow diverse sources of data to be 
integrated into the decision, including statistical information 
from the clinical literature, personal clinical experience and 
patient values; 4) they offer a way to examine the impact of 
assumptions or soft data on the decision, through sensitivity 
analysis; and 5) they provide a forum for discussing clinical 
reasoning and developing a consensus among groups of 
decision-makers (which in this case included the patient, his 
internist and his urologist), whose backgrounds, areas of 
expertise and objectives may be quite disparate. 
Summary. Decision analysis tools for the individual pa- 
tient exist and are easily applied to common problems in 
clinical cardiology. The analysis that we demonstrated is 
that of a real patient who was seen on a cardiology consul- 
tation service and whose care was based on the analytic 
results. The methodology for such analyses is tractable and 
allows the physician to integrate survival data with the 
preferences of individual patients. Beyond the identification 
of optimal treatment strategies, the method offers the deci- 
sion maker the unique opportunity to gain insight into the 
trade-offs that are implicitly made in selecting among treat- 
ment strategies. The use of such tools can improve the 
quality of clinical decisions. 
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